A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
A study to evaluate safety and biologic effects of giving GRN163L in combination with
trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to
therapy with trastuzumab.
Phase:
Phase 1
Details
Lead Sponsor:
Indiana University
Collaborators:
Breast Cancer Research Foundation Geron Corporation